GvHD
45
5
5
24
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
12 trials with published results (27%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
8.9%
4 terminated out of 45 trials
85.7%
-0.8% vs benchmark
16%
7 trials in Phase 3/4
50%
12 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (45)
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population
Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
Haplo Peripheral Blood Sct In GVHD Prevention
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Autologous Serum Obtained by a Closed-Circuit Collection Device
The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD